APA (7th ed.) Citation

Wang, D. D., Naumova, A. V., Isquith, D., Sapp, J., Huynh, K. A., Tucker, I., . . . Kim, F. (2024). Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure. Cardiovascular diabetology, 23(1), 197-9. https://doi.org/10.1186/s12933-024-02294-z

Chicago Style (17th ed.) Citation

Wang, Dennis D., et al. "Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes Without Known Heart Failure." Cardiovascular Diabetology 23, no. 1 (2024): 197-9. https://doi.org/10.1186/s12933-024-02294-z.

MLA (9th ed.) Citation

Wang, Dennis D., et al. "Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes Without Known Heart Failure." Cardiovascular Diabetology, vol. 23, no. 1, 2024, pp. 197-9, https://doi.org/10.1186/s12933-024-02294-z.